Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)
China flag China · Delayed Price · Currency is CNY
32.37
-0.13 (-0.40%)
Oct 23, 2026, 11:30 AM CST

SHA:688336 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
4,4564,1801,1791,005817.88928.12
Other Revenue
19.1219.1214.899.27.610.69
4,4764,1991,1941,014825.49928.81
Revenue Growth
226.65%251.81%17.71%22.84%-11.12%41.80%
Cost of Revenue
336.04332.46304.7223.04204.81210.02
Gross Profit
4,1403,867888.86790.99620.68718.79
Selling, General & Admin
280.41299.71316.73314.89333.18367.15
Research & Development
542.11434.95356.49282.3313.28455.09
Other Operating Expenses
-8.7311.699.39.376.234.11
Operating Expenses
813.67746.1682.29599.78658.18827.58
Operating Income
3,3263,121206.58191.21-37.5-108.79
Interest Expense
--0.57-1.18-1.4-1.32-
Interest & Investment Income
31.2384.3255.8139.642023.94
Earnings From Equity Investments
140.9676.36395.8-16.4-15.48-3.28
Currency Exchange Gain (Loss)
-40.93-40.93-3.180.963.38-0.8
Other Non Operating Income (Expenses)
-41.2-0.15-0.27-0.17-0.11-0.18
EBT Excluding Unusual Items
3,4163,240653.56213.84-31.02-89.12
Gain (Loss) on Sale of Investments
88.0450.5528.9319.435.4624.2
Gain (Loss) on Sale of Assets
-0.73-1.090.1256.39-0.94-12.98
Asset Writedown
-0.31-----
Other Unusual Items
23.9629.4825.042125.4624.5
Pretax Income
3,5273,319707.66310.6328.96-53.39
Income Tax Expense
441.92426.6816.2627.27-16.48-51.69
Earnings From Continuing Operations
3,0852,892691.39283.3645.43-1.7
Minority Interest in Earnings
2.917.4513.1911.253.8619.75
Net Income
3,0882,899704.58294.6149.318.06
Net Income to Common
3,0882,899704.58294.6149.318.06
Net Income Growth
254.77%311.50%139.15%497.63%172.99%-
Shares Outstanding (Basic)
887894896890893872
Shares Outstanding (Diluted)
890898896890893872
Shares Change
-2.70%0.24%0.69%-0.34%2.37%2.38%
EPS (Basic)
3.483.240.790.330.060.02
EPS (Diluted)
3.473.230.790.330.060.02
EPS Growth
264.63%310.53%137.52%499.64%166.67%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-72.052,7910.35180.6112.23-507.61
Free Cash Flow Per Share
-0.083.11-0.200.01-0.58
Dividend Per Share
0.3100.3330.0850.035--
Dividend Growth
265.92%292.81%145.80%---
Gross Margin
92.49%92.08%74.47%78.00%75.19%77.39%
Operating Margin
74.31%74.31%17.31%18.86%-4.54%-11.71%
Profit Margin
68.99%69.05%59.03%29.05%5.97%1.94%
Free Cash Flow Margin
-1.61%66.45%0.03%17.81%1.48%-54.65%
EBITDA
3,4463,244334.54287.384.9126.66
EBITDA Margin
77.00%77.25%28.03%28.33%10.29%2.87%
D&A For EBITDA
120.09123.47127.9796.08122.41135.46
EBIT
3,3263,121206.58191.21-37.5-108.79
EBIT Margin
74.31%74.31%17.31%18.86%-4.54%-11.71%
Effective Tax Rate
12.53%12.86%2.30%8.78%--
Revenue as Reported
3,0834,1991,1941,014825.49928.81